![Teva Canada announces the launch of AJOVY™ for the preventive treatment of migraine in adults who have at least four migraine days per month Teva Canada announces the launch of AJOVY™ for the preventive treatment of migraine in adults who have at least four migraine days per month](https://mma.prnewswire.com/media/1160028/Teva_Canada_Teva_Canada_announces_the_launch_of_AJOVY__for_the_p.jpg?p=twitter)
Teva Canada announces the launch of AJOVY™ for the preventive treatment of migraine in adults who have at least four migraine days per month
![Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210408005437/en/713670/5/teva_RGB_JPEG.jpg)
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
![Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults | Business Wire Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults | Business Wire](https://mms.businesswire.com/media/20210623005566/en/739014/23/teva_RGB_JPEG.jpg)
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults | Business Wire
![PDF) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs PDF) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs](https://i1.rgstatic.net/publication/355584267_CGRP_monoclonal_antibodies_in_migraine_an_efficacy_and_tolerability_comparison_with_standard_prophylactic_drugs/links/61778e693c987366c3e9bbe3/largepreview.png)
PDF) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
![No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1631128798/AJOVY%20Image.jpg/AJOVY%20Image.jpg?VersionId=syVEFjOv7_Oy_I9QN1IbMNNg6mpwQsTc)